These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7786521)

  • 1. Treatment of psoriasis with anthrones-chemical principles, biochemical aspects, and approaches to the design of novel derivatives.
    Wiegrebe W; Müller K
    Skin Pharmacol; 1995; 8(1-2):1-24. PubMed ID: 7786521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsoriatic anthrones: aspects of oxygen radical formation, challenges and prospects.
    Müller K
    Gen Pharmacol; 1996 Dec; 27(8):1325-35. PubMed ID: 9304402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure specificity of the antipsoriatic anthrones.
    Krebs A; Schaltegger H; Schaltegger A
    Br J Dermatol; 1981 Aug; 105 Suppl 20():6-11. PubMed ID: 7284267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyl radical damage to DNA sugar and model membranes induced by anthralin (dithranol).
    Müller K; Gürster D
    Biochem Pharmacol; 1993 Nov; 46(10):1695-704. PubMed ID: 8250955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals.
    Müller K
    Biochem Pharmacol; 1997 May; 53(9):1215-21. PubMed ID: 9214681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and recent developments in anthracenone antipsoriatics.
    Müller K
    Curr Pharm Des; 2000 Jun; 6(9):901-18. PubMed ID: 10828315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
    Müller K; Leukel P; Ziereis K; Gawlik I
    J Med Chem; 1994 May; 37(11):1660-9. PubMed ID: 8201600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsoriatic effect of dithranol (anthralin). 1].
    Raab W
    Hautarzt; 1975 Sep; 26(9):452-5. PubMed ID: 1184389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris.
    Kemény L; Ruzicka T; Braun-Falco O
    Skin Pharmacol; 1990; 3(1):1-20. PubMed ID: 2202336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and characterization of 9-anthron-10-yl radicals formed by antipsoriatic and tumor-promoting 9-anthrones in aqueous buffers.
    Hayden PJ; Chignell CF
    Chem Res Toxicol; 1993; 6(2):231-7. PubMed ID: 8386561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone).
    Mustakallio KK; Brandt H
    Acta Derm Venereol; 1984; 64(1):63-6. PubMed ID: 6203285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships for the formation of secondary radicals and inhibition of keratinocyte proliferation by 9-anthrones.
    Hayden PJ; Free KE; Chignell CF
    Mol Pharmacol; 1994 Jul; 46(1):186-98. PubMed ID: 8058052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free radicals and the treatment of psoriasis with special reference to dithranol.
    Mustakallio KK; Martinmaa J; Vilvala R; Halmekoski J
    Med Biol; 1984; 62(2):155-8. PubMed ID: 6471937
    [No Abstract]   [Full Text] [Related]  

  • 14. Antipsoriatic drug action of anthralin: oxidation reactions with peroxidizing lipids.
    Ducret F; Lambelet P; Löliger J; Savoy MC
    J Free Radic Biol Med; 1985; 1(4):301-6. PubMed ID: 3836247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthralin derivatives--inhibition of 5-lipoxygenase--antipsoriatic efficacy.
    Tanzer H; Braun C; Seidel M; Wiegrebe W
    Arch Pharm (Weinheim); 1991 Nov; 324(11):841-6. PubMed ID: 1804060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antipsoriatic effect of dithranol (anthralin). 2].
    Raab W
    Hautarzt; 1975 Sep; 26(9):456-9. PubMed ID: 1102494
    [No Abstract]   [Full Text] [Related]  

  • 17. Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
    Müller K; Gürster D; Piwek S; Wiegrebe W
    J Med Chem; 1993 Dec; 36(25):4099-107. PubMed ID: 8258834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsoriatic anthrones with modulated redox properties. 3. 10-thio-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of keratinocyte growth, 5-lipoxygenase, and the formation of 12(S)-HETE in mouse epidermis.
    Müller K; Huang HS; Wiegrebe W
    J Med Chem; 1996 Aug; 39(16):3132-8. PubMed ID: 8759634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immunohistochemical assessment of the response of the psoriatic lesion to single and repeated applications of high-dose dithranol cream.
    Swinkels OQ; Prins M; Gerritsen MJ; van Vlijmen-Willems IM; van der Valk PG; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2002; 15(6):393-400. PubMed ID: 12476013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
    Müller K; Reindl H; Breu K
    J Med Chem; 2001 Mar; 44(5):814-21. PubMed ID: 11262091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.